Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.
Läs transkriptioner från webbsändningar och audiocasts
Läs transkriptioner från webbsändningar och audiocasts
Ansvarsfriskrivning: Detta är en maskingenererad transkription och kan innehålla felaktigheter.
Thank you. This is Peter Forsell here, and I will start by providing a short background as I normally do. It may not be so interesting for those who listen repeatedly, but I need to cover it for the new listeners. I am the founder of Implantica and this is my second implant business. The previous one was a gastric band, which was very successful. We took 28% of all non-U.S. market share in obesity surgery, and then it was sold to J&J. I have invested part of the money I received at that time. So more than €100 million of personal funds have been invested in this company, which means I strongly believe in this. I am also the inventor of the RefluxStop device. RefluxStop is our main and first product, and it is now FDA approved, which is very exciting, and I will soon come to that. I will just start by giving a short background of the treatment area and the product before we go on. So today, we have 60 hospitals in Europe performing this procedure, and we have completed approximately 2,000 procedures. It is a relatively simple operation. One hour. It takes approximately one hour, and the patient goes home the next day. And we have a fantastic 98% success rate. It is an incredibly successful treatment with our device. And GERD, which is called gastroesophageal reflux disease, is the largest treatment field in the world. There are 1 billion sufferers of this disease. And in the United States, where we are now entering the new market, there are 78 million people. 23% of the population has this disease. And that is an astonishing amount of people. Also, this disease is not just about experiencing pain because acid from your stomach comes up into your esophagus, burning the lining and causing small ulcers, discomfort, and other symptoms. But it's also a dangerous disease. You get cancer from this disease because you are traumatizing your tissue with acid over and over again. That is a classical textbook example of how you create cancer. So if you take a gastroscope and look, 10% to 20% of patients have pre-cancerous changes. So this is not just a simple disease. It is a dangerous disease as well. 48,000 people in Europe and the United States combined basically die from esophageal adenocarcinoma. So, 48,000 people. Now, finally, there is a treatment. So we can change this. And that is what it is all about here. If you look at existing treatments, you have medical treatments that reduce the production of acid. And that means you get less acid in your reflux, so you have less pain. But that is it. It does not treat the disease. You still have your reflux. You still have your regurgitation. You still damage your tissue with gastric fluid, and you still have your cancer risk. There are many complications associated with these drugs. Deadly complications. Actually, in a huge study from the United States of 157,000 US veterans, 7,000 extra deaths were linked to the medication. So it is really not something you want to take for the rest of your life. Surgery in the past was focused on that. You should help to close this sphincter. The sphincter between the stomach and esophagus is weak. We need to support its closing. So Doctor Nissen, already in 1956, he performed a Nissen fundoplication. He wrapped the top part of the stomach. It was like the Nissen fundoplication. He wrapped it around and put pressure on the sphincter to help it to close. And we have today a product from J&J, our main device competitor called LINX. It is an MSA magnetic band, and it does a similar thing. It tries to support the closing here. The problem now is that this is the patient's food passageway. That means you have difficulty swallowing your food, and you cannot burp or vomit. You cannot. You can't burp. Altogether. The air you swallow with your saliva and food stays. So you get bloated. And people are quite unhappy with these types of surgeries, and they do not treat the reflux very effectively either. So this technique assumes that the sphincter is weak and that you need to support its closing. That is old school. That does not correct what we have showed; what you actually need to do is to treat three components that comprise the acid reflux barrier. One of them is the sphincter, but it's the position of the sphincter, not the weakness of the sphincter. What is the problem? And here you see how you place our device. RefluxStop. It is placed on the outside of the stomach at the top part of the stomach, and it acts like a little reinforcement parallel to the food passageway. So we do not affect the food passageway at all. So people can eat normally, swallow normally, belch and vomit normally, and so on. But this acts as a mechanical stop towards the diaphragm, and the disease itself is caused by the sphincter sliding up. So when this sphincter glides up and comes closer and closer to the diaphragm, you get more and more acid reflux. And that is because in the chest, you have pressure variations from breathing. You breathe in, you breathe out, in, out. That is quite strong pressure up in the chest. And acid leaks out here because the diaphragm is moving when you are breathing. So you need to have a hole around the esophagus here so it can pass through. And then the pressure variations leak out here and traumatize this sphincter and it cannot handle it anymore. So if you look at the small middle picture here, you see that the sphincter has been gliding all the way up into the chest. Then you call it a hernia. And this means that this sphincter cannot close at all. It is like a highway for acid to go up and damage the tissue above the stomach, basically. This is a unique treatment. And that is what we now hope to launch in the United States. So if we look at the situation for this launch, we are in a better position than a typical American company when preparing for their market entry. And that is because of a few different topics. So, first of all, we have very long-term data. We have produced five-year data, and we even have seven-year data. We have safety data for more than 600 patients. We are in a fantastic position, unlike a typical U.S. company. I can give you Inspire Medical as an example, a snoring device that came out in 2014, and they only had one-year data. And then it takes three to four years with small revenue before it takes off, because you need to create your five-year data. No one wants to perform tens of thousands of procedures if they do not have long-term data. This is too risky for the patients. So this is a very important factor why we can do a much faster and quicker launch in the United States. Also, we have been attending all the major meetings and congresses to present our data. European surgeons have been flying over to attend all the US congresses, and surgeon after surgeon has presented the data. Today, we have more than 40 articles from different centers, and every single article presents fantastic data. No single article with poor data has been published so far. Out of these 40 articles, we have been able to convince both the society and the surgeons in the United States. This is it. This is what we are looking for. So we have more than 100 surgeons waiting to start. So we are in a fantastic situation. We don't need to do any sales work. It is just a matter of getting these centers started. Also, when a normal U.S. product comes to market. They have no codes. No one pays for the procedure. We have existing codes. We are paid for the device. They. We are not paid for the device. The surgical procedure and the. The. The doctors. Surgeons are paid separately. They are also paid. But the device is not covered. But everything else is already paid for. Also, we have superior health economics, which means societies save money if they transition patients who currently take medication to treatment with RefluxStop, as they will save money by avoiding the significant costs associated with complications that society otherwise needs to cover. So that is a fantastic situation where we can approach the insurance companies and request coverage for this device. That is why we have produced 13,000 devices to be ready for a real splash in the U.S. market. And it is completely unique. We have been able to obtain FDA approval using European clinical data. It was 30 years ago that the FDA last approved a device based on European data. And why are they suddenly approving our device with European data? The answer is easy. We have fantastic results. And that is what I will show you a little bit later here as well. Here you see the launch; we launched at the American Foregut Society meeting on September 25th in Washington. We held a symposium, which included many speeches and posters. We had a symposium of 1.5 hours. We had planned for 100 people. We had to close the doors when there were 126 people in the room. There was enormous interest. Previously, I have hosted this symposium. We had fewer people, and people were quite critical. How do you expect that you can treat acid reflux if you don't close the food passageway and so on? And no one really understood how it actually works. Now, at this meeting, there was not one single critical question from any one of these 126 people. The only question we have is when can we start? So it is hard to describe the enormous interest. I was personally at this meeting. I had a meeting room. I was able to have a meeting with 30 centers who want to start. I could have met 90 centers that want to start, but there was no time. I have been occupied the entire time with meeting after meeting. Everybody wants to start. Everybody wants to be the first to start. You cannot imagine the interest we have in the United States for these products. Here are the first centers, including Chris DuCoin here. He was unable to attend our training, but all the others here have gone through European training to become the first selected sites that serve as training centers for others. And here, you see, we performed the first surgeries at Professor John Lipham's center. This is the University of Southern California, USC, actually called Keck Medicine of USC. And you see Professor Lipham standing here, and you see me looking a little bit more tired here. It was really fun. And we are now planning, of course, to start Centers of Excellence. It is just that they need to finalize the paperwork. You know, in the United States, it is a litigious country. There are many legal requirements that need to be addressed. So to start at the hospital, it doesn't matter that the surgeon wants to do it and we want to do it. There are different committees you need to pass, and you need to reach an agreement with the hospitals. So it is a bit of a startup phase, but we are step by step bringing them on to get more and more centers. And it will of course be an exponential, what we call when it expands like an L-shaped curve here, as soon as they get ready with the bureaucracy to start. And here you see the centers we have selected. So here you have the centers I talked to and some more. And we are doing this in ways that we will start systematically to perform this to reach the 100 centers as early as possible. And we believe that when we have reached the 100 centers, we will probably have another 200 to 300 centers who want to start. So the sales work will be the least of our problems. What is most important is the quality. We need to ensure that everybody performs the surgery perfectly, and we need to ensure that they do not repeat the mistakes we made in Europe. No one should make any mistakes that we are aware of now after these 2,000 cases. So this is the absolute key. Ensure now that we show that this is really the procedure without side effects and complications. We are also building a fantastic team. We have already created a really strong team. And that is because LINX is our main device competitor. As you know, they have withdrawn from all markets outside the U.S., and there is a consensus that they will disappear from the U.S. market as well. And therefore, all their salespeople and important leaders come to us and want to join our team. So we have a long list of people who want to work for us. And we have selected the head of sales. We have people here who personally know that LINX, at its peak, served approximately 400 hospitals, but usage declined due to significant side effects, with a reported 30% to 50% complication rate. But these people know personally every single doctor and every single center. When I was at the University of Southern California here, for example, our salesperson in that region knows everybody, the nurses, the doctors; it is incredible. And that is a fantastic relationship to have. We have now selected these heads of sales, and they have all committed to establishing the first 100 centers without any additional support. We don't need any more salespeople than these heads of sales divided into four or five regions of the United States. That is all that is required to establish the first 100 centers. Then, of course, in the long run, we aim to create maybe 1,000 centers or whatever it will be in the end. Then you will need a team of people under each of these leaders. And please do not treat the number of centers as a confirmed fact. We just see step by step how many centers will be doing this. We have a fantastic training program, and that is what we have been running on. The first six agents. They are well trained, having developed the program over a long time and tested it in Europe, and it is a very interactive and nice training program. To really succeed in the United States, there are three key areas. Of course, it is the physicians and I would say the surgeons. We have already convinced them. So we do not need to do much more work. Everybody knows about RefluxStop and so on. That is a checkmark. I would say the GIs are the medical doctors who refer patients. They are many, many more. We still have a lot of work to be done, but we have come very far. I will show you some work that they have done for us, for example. So continuous work, but very successful so far. The next step is direct-to-consumer marketing. So in the United States, you are able to do direct-to-consumer marketing to patients. This is not permitted in Europe. In this case, this is very important because that will reach all the patients, representing nearly between one-fifth and one-quarter of the population. They will come to all the hospitals and want the surgery. So it will be enormous pressure on these hospitals with all these patients. We have done one marketing campaign in the UK, although we are not allowed to do direct-to-consumer marketing. But we managed to do it with patients appearing on TV news programs, doctors being interviewed, and lots of articles in the press. And we have been very successful. So our lead surgeon in the UK, for example, Dr. Ahmed from Imperial College, says he gets patients directly because they know about RefluxStop today. It really has a good effect, and it will be even better, of course, when you can market directly to customers. What is important, and because I am now talking about the UK and also what is important for the future, is of course that our market is ten times larger than our competitor's market. So if there are 30,000 procedures performed in the U.S. today, it is not only a heavily compressed market due to the high frequency of side effects and complications. It would maybe be 300,000 surgeries, but also our market is ten times larger than that. And because of that, the half that are being operated on today are the mild sufferers. It is the worst of the mild cases that are included in those 30,000 surgeries. The other half have been damaged in their esophagus by the acid. So they have poor esophageal motility function. The nerve ends and the muscles. The acid is extremely strong. The acid damages the muscles and the nerve endings. So they have a very weak food transportation. And remember, existing methods all try to close down. And then you come with your weak food transportation. And it stops down here, so it does not work. So they have no treatment whatsoever. And that is why NICE, after a nine-month review of RefluxStop, stated we should have this product in NHS public hospitals for this group of sufferers who currently have no treatment options. And here you have all the severe sufferers, all the long-term sufferers. The surgical need here is ten times larger than this group, and they have no treatment. So that is the future for us; of course, the potential is enormous here. I wanted to show you a very interesting article relating to the NICE approval here. These are two American gastroenterologists, also medical doctors, one from Harvard and one from Washington University Hospital. These are also very respected medical doctors in the United States. They have taken data from the largest university in Switzerland, Inselspital, from Doctor Yves Borbely, and analyzed his patients. He has operated on a large number of these patients with poor motility. In reality, he operated on 44 patients with poor motility and five patients without motility. They have no contraction whatsoever in the esophagus, nothing that transports food down. And compare that to 33 with normal motility. And here you can see the outcome. These are extremely interesting results. You can see here that the columns to the left represent the degree of symptom reduction. And then you can see that there is between an 80% and 90% reduction of symptoms after one year, and even higher, between 90% and 97%, thereafter. Even with reduction at two years. These are two-year results, and you see that they are more or less the same. Whether you have the group with poor motility or not, the outcome is very similar, and if you look at the picture to the right, this is the quality of life formula. It is a questionnaire. Focus a little bit on reflux, but it is quality of life. And then you can see how it has improved dramatically after one year. It continued to improve after two years. It is the same, even if you have this terrible disease with hypomotility. It is the same outcome. And if you look at the middle chart to the left, you see swallowing difficulties, and you see they have no swallowing difficulties left. It is incredible. They are nearly normalized, nearly all of them. These results are so astonishing. So it is hard to believe. These are incredible results. And these medical doctors here in the U.S. are super enthusiastic and they want to do more research. More articles. This is just an incredible outcome. So it is fantastic. It is simply objectively fantastic. If you then look at our market, you see here we have in the United States maybe 340 million people, 78 million of whom have this disease. And in this little setup here, I have only used those who are not treated by medication. As you know, 40% are not treated by medication at all. And that is because the medication does not treat the reflux. It also reduces the acidity. But these 40% objectively measured have a bad pH level. The acid is still refluxing in these patients. Studies have been conducted on that. So you have 40% who are not helped. We are only focusing on this segment for now. Although as you know, with all the risks of cancer and other complications, everyone suffering from this condition should be treated surgically. But let's now focus only on those who are not treated. And you can see here that today there are around 30,000 procedures done in the United States. That means we have a penetration of 0.1%. This is the lowest, lowest, lowest figure you can imagine in the United States. Normally, they have at least 3% penetration in the surgical field. And if you take 1%, then you have 300,000 procedures that would normally have been done by the competition we have today. If it were not for the fact that current treatments have such high rates of side effects and complications. Otherwise, it would already be 300,000 with our procedure. It is easy to expect that it will be. You can do much more than that. So we have made an example here of 3%, which is 900,000 procedures and 7.4 billion in revenue in such a case. These are just examples. However, this is not a promise of anything. It just shows you what happens if you are able to achieve a certain penetration. So no promises. What we will succeed with. I am just giving you examples of what could happen if you succeed in this way. If you then look at the clinical outcome, we have some more interesting new data I wanted to show you as well. First of all, this is just a comparison of the safety data. This data is displayed to the right. Here is our study. We filed our PMA application with the FDA in the United States. And you see that the safety data is more or less 100%. And in our study, we had one re-operation where the suture came loose. It was an elective procedure; there were no other complications in the real-world data. This data is from 22 centers. It is 602 patients. And here you can see that the results are more or less the same. Okay. It is not 100%. It is 98.7% and 99.3%. But it's basically the same, which means that this procedure could spread to many, many different centers and surgeons, and they will do the right thing. Normally, when you move to the real world, the results are much worse. It could be 70% or 80%. These are very, very promising figures. Of course, we have our FDA data; as you know, they are published. I showed you this before, but I am just giving you the reference here for the two published articles that reflect the FDA data. I just wanted to show you one figure. And this is the only objective way you can measure if you treat acid reflux or not. And this is the same test that our main device competitor was using in their FDA trial. You can read the FDA memorandum published for this FDA trial of our competitor. And you can see that 36% of the patients failed this objective pH test, where you measure pH over 24 hours in the lower esophagus. In our PMA study, no one failed this test. Zero patients failed the objective pH test, compared to 36% by our main device competitor with the same test, both in the FDA study. That is an achievement. Now comes a very new, very interesting study I wanted to present to you. And this is Dr. Renzi, who has conducted a comparative study between RefluxStop and Nissen. And here you can see the data before surgery. You can see that these are very well-matched groups, with more or less identical data on all parameters before surgery. And then you can see the outcome after one year. And you can see the difference here. It is not a small difference here. It is more or less like night and day. So if you take, for example, swallowing difficulties, 21.4% of patients had swallowing difficulties. At the one-year follow-up, zero patients experienced swallowing difficulties in the RefluxStop group; regarding PPI use, 95% of patients in the RefluxStop group discontinued use, while 78.6% of the control group continued to take PPIs. Quality of life is much higher, 86% compared to 65%, with bloating at 31% compared to 4.9%. Inability to belch was 31% compared to 0%, and the re-operation rate was 6.5% compared to 2.3%. All this data you see here is statistically significant. That means it is proven data. We are talking about proven data here. This is approximately what we have seen in all the studies that have been published. All literature reviews were done with our competitors. It is a similar result with the 40 published articles I already mentioned. Incredible hard work from our surgeons. There are 22 more manuscripts in the pipeline. As you know, we are more cost-effective. So when we go to the insurance companies in the U.S., we can ask if they want to save money or not. If you want to save money, you need to switch treatment. That is powerful. Also, we have, of course, all the pipeline products in this company. We are not just a single-product company. We have a fantastic eHealth platform. It has taken eight years to develop this, and it is very advanced. It allows us to control patients' health from inside the body, remotely and from a distance. And you can also build the most fantastic implants. We have filed 25,000 pages of patents to protect this eHealth platform. And we have been busy doing just that. There are over 300 connected inventions demonstrating how we can improve healthcare with this platform technology. We can easily develop a product portfolio of the same magnitude as Medtronic from these pipelines we have. So there is more to come, but for the moment, the focus is only on the RefluxStop US launch. We are not doing anything other than the U.S. launch. We want to show our investors that we can become a very successful company, and they could see significant returns on their share investment. That is the priority. And this is just an example of two products. I think you know this product, but for new listeners. For people who use a stoma bag, they don't need this anymore. They only need the remote control. And for our device, people who cannot urinate currently use a catheter five times per day to empty their bladder. They do not need that anymore. They need our device. And the remote control will change and revolutionize these people's lives. But we are focusing on RefluxStop for the moment. But at some point in time, we will change the world. In terms of the healthcare finance update, I give the word to our CFO, Andreas Örnberg.
Thank you very much, Peter. Good afternoon everyone. I will share our financial performance for the third quarter of 2026. Net sales for the quarter were €748,000, up 105% from the third quarter of 2025. The growth was driven by the activation of new centers in Germany and in Spain, as well as higher penetration at existing centers, as discussed by Peter earlier on this call. The first RefluxStop procedures were successfully performed in the U.S. after the quarter end, and we are continuing to onboard new U.S. surgeons. The new US centres will not be charged for the devices used for the initial training. Our priority is to build a broad user base and to ensure that surgeons are thoroughly trained to achieve excellent patient outcomes. Implantica consistently delivers best-in-class gross margins. The adjusted gross margin for the quarter came in at 94%, up one percentage point on the same period last year. Given the margin profile that we see, we expect to benefit from significant operating leverage as we scale. The third quarter operating loss amounted to Euro 4.5 million, a modest 2% increase compared to Q3 2025. The increase was driven by higher operating expenses, led mainly by R&D, investments in data collection, and DTC marketing spend supporting the U.S. market launch. Turning to cash and cash flow, operating cash outflow amounted to Euro 3.4 million for the quarter, a 3% increase compared with Q3 2025 at quarter end. We held cash and short-term investments of Euro 38.3 million. We continue to have no interest-bearing debt in the capital structure. Let me comment on our shareholder base. We are supported by a committed, high-quality investor base, including our founder and CEO, Peter Forsell, and other members of the management team. We value the continued long-term support as our team relentlessly works to ensure that GERD sufferers worldwide gain access to the best available treatment at scale. With that, let me hand it back to you, Peter.
Yeah. Thank you. So I think it is time to thank you for listening. And as always, we take a bit longer than expected, but we appreciate your questions and we will do our best to answer them. Thank you.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.
Hi. Good afternoon. I've got a bunch of questions today, but I'll take them one by one and you let me know if there's too many. So just stop me then. But firstly, just on the first procedure now done by John Lipham. Just wondering what has been the feedback. And then I am also wondering, is the workflow any different, or is there anything else that differs in the U.S. compared to Europe around this?
So, the feedback has been fantastic. Dr. Lipham even traveled to Europe to observe the next training session we conducted with the other surgeons. So he was involved in that as well. And he even had a little video presentation where he showed his procedure and the learnings he has made to the other surgeons. It is very positive overall. It is exciting times. They are booking more patients.
Okay. How many procedures has he done so far? I am also wondering now that he has done the first, is he going to continue with more patients now. Is it fully up and running?
Absolutely. He performed three surgeries initially. I was there for these three surgeries.
Okay. So for his hospital, that contract is already in place. Is that how we should interpret it then?
So, the U.S. healthcare landscape is quite complicated, and I believe it is a bit too much to explain in detail to this auditorium exactly how it functions. But it is a process where the hospital approves. You have something called, I believe, an Institutional Review Board. You have something called the VAC process, and everything follows established routines. It is quite bureaucratic, but also very stringent. It is a very rigorous process. And this you need to pass in terms of John Lipham's hospital. He can now continue to do more and more surgeries by booking more surgeries. I will travel to the United States again later. Of course, it will not be me doing this. It is just that I think it is a bit fun to be involved here in the beginning. We have eight European surgeons willing to do that, and we are now employing a U.S. surgeon as well to support us. It is exciting in the beginning to be involved.
Okay, great. And I was wondering, more on the demand side, do John Lipham and these other newly trained surgeons already have patients on a waiting list for RefluxStop? I am wondering, he did his first three cases. How did those patients find their way to him?
He has a long waiting list with RefluxStop patients. But as you know, you need to pass the formalities as well. That is just how it is. No, he will operate a lot, I think. But as you know, we have requirements to become a training center professor. Lipham will become a training center so he can train others. And that means he needs to have a bit of extra training. And this training process takes a little bit of time to get everybody trained before they can take off. So to speak. You cannot just rush into things, you know. And let people operate without overseeing what is happening. That is not the smart solution. You need to be involved and ensure that they receive high-quality training. Then you know, they will take off like a rocket for us. Fantastic. And I can tell you that we actually have got the IRB approval for something called Western, which means that most hospital sites are set.
They are IRB approved, which means that we are quite far.
Far in the bureaucratic world to get going. So that basically means that most centers now should be able to start. It is just the internal process that is also needed.
Okay, good. Is there any?
I mean, if.
You are asking about revenue; it is not that we have significant revenue in the coming months. That is not what it is about. It is about building the business. We are currently focusing on training the surgeons. You know, we are building for something that will come. And at one point, this will explode.
Yeah.
We provide the RefluxStop devices for the training surgeries free of charge. Because if we are not provided them for free, we would be delayed several months by bureaucratic processes, and therefore, we have circumvented that. A certain amount of approvals are needed, even for the training surgeries, but there is even more to do with permanent procedures later on. Therefore, we have decided that every single center will receive ten products for free, and in this way, we can require that the centers allow us to be involved. You know, a typical surgeon, especially surgeons who are as competent as these people, think, okay, now we've done three surgeries. Now I can perform this procedure. I do not need any more training. That is the general surgical approach because they are so competent. However, we are not satisfied with that approach. We want to follow them for ten surgeries to ensure that we really get the perfect quality. To achieve this, we provide them with ten RefluxStop devices for free, because that allows us to stipulate that they only receive the devices at no cost if we are involved and oversee their surgeries. That is the key here. We need to be able to ensure the quality, because the United States is a country where they sue people. It is a country where you can get a bad reputation if you do not ensure perfect quality. So that is why every center that is starting now will perform ten surgeries quickly. Ten surgeries. But those first ten are not generating revenue. They are training surgeries.
Okay. Very clear. I was just trying to get some sense of the demand situation. So you are going to start off with the demand situation.
You know, it is enormous. I can take the eight surgeons and go to the United States, and we can travel around for three months. However, we first need to get the approval process finished. But a big step, which we actually received just yesterday, was obtaining this IRB approval for an organization called WCG that oversees it for all hospitals, so to speak. So that is a centralized approval and that is very favorable for us.
Okay. But is it possible to quantify it a bit? How many patients does the doctor have on their waiting list? On its waiting list. And I suppose you have gotten some inquiries direct to you as well, through emails, etc. . Now, is it possible to quantify roughly how many patients there are?
He has many on his waiting list. You know this hospital, they do 1,100 procedures every year. He is employing two more surgeons because he believes he will do more surgeries than that because of RefluxStop. So, you must understand it is not a coffee break. We need a little bit more time to build this step by step, and this needs to be done, as I said, with quality. And I think maybe you and I need to have a separate discussion, because I think it is maybe a bit too much for this call. Yeah.
Okay. So it sounds like we shouldn't expect any U.S. revenue now in Q4 because you are providing the devices for free. But is it possible to provide some information then? When should we expect some first U.S. revenue then? Revenue then?
Yes, once they have completed the training surgeries, revenue will start. That is the plan. So the training surgery is done first. And that is because then we can ensure that we are invited to join via live streaming or be present, as we want to do this very carefully and successfully.
Okay. Clear. And I think just the last question for me is around the costs here. So, SG&A expenses remained flat in Q3 versus Q2. And I saw you had eight new U.S. hires. hires. So is it reasonable to expect SG&A costs to step up from Q4 onwards? That was also one point. What are the plans for future hires and spending in the coming quarters in 2027 as well.
We have done a little bit. We have implemented a cost-saving program, as we are trying to reduce expenses to improve efficiency. And this FDA process has incurred significant extra costs. As you know, it costs a lot to do this approval process. So it is a little bit balanced between the reduced costs and the increased costs. But it is clear that these people we employ now in the U.S. cost something. That is clear. But as I.
Said.
We are not employing a full sales team. We have gone the other way around. We select top sales personnel who have personal relationships, have been working for 20 or 25 years in this field, and know every surgeon; they have promised that for the first hundred centers, they will conduct the procedures themselves and will not need additional employees. So it is not like we need to employ 50 employees for sales. But we can have a more detailed discussion, perhaps between you and me.
Okay. Very good. Thanks. Then that is all for me.
Thank you.
The next question comes from Ed Hall from Stifel. Please go ahead.
Hi everyone. Good afternoon. Yes, I just have one question regarding the sales professionals that you have hired. I want to better understand how you are thinking about the steps required to convert these first centers. Maybe you could just elaborate on what these individuals are actually doing. I appreciate they have these great relationships, and it probably makes it a bit easier. So, how long is that conversion expected to take? And is it the ten surgeries that you mentioned that they will be sitting in before they are, let's say, independent? Um, yeah. Any color around that would be quite helpful. Thank you.
Yeah.
So all the new hires were attending our training we had in Frankfurt last weekend, Sunday and Monday. Together with the U.S. surgeons and the U.S. salespeople, we had a full day on Sunday training, reviewing videos, explaining mistakes that have been made, and going through the whole procedure in exact detail. Then on Monday, we performed three surgeries. We have been busy. We had selected a hospital, and Dr. El-Shafei Mustafa was nice enough to take us all in because they have very large operating theaters, and he is a very competent surgeon. We observed three surgeries together. So we have a really good start. And of course, the salesperson from the Western United States was part of the surgeries when I proctored the professor for the three procedures. They of course need to see a few more surgeries, but they will now join all those where a proctor will come, such as our European surgeons or me. And at some point it will be Professor Lipham, who may be the first to perform enough training surgeries to become a proctor himself. So I think it will go relatively easily. But of course, it is a process to ensure that everybody is well trained; that is clear. But what we have achieved now is that we have recruited top-class people who started as sales representatives and have grown through the ranks to become heads of sales because they have power, energy, and intelligence. And these are the people we are working with now. So we have a fantastic team. And that means a lot, actually.
They are very clear. And maybe just on the timeline, purely on the administration side. I appreciate that the surge in interest is really high. But how long is that process in terms of weeks or months before we should expect to reach full approval rather than just the training?
Yeah. So to start the training, certain approval is needed. But that seems to have passed for most hospitals now, and then there is some internal approval as well. But that goes relatively quickly to be able to start the training. As long as we supply them for free. If we had charged money for the training, it would have taken a longer time to get them trained. That is why we are doing it for free, so we can quickly get going. That is the problem we have. To answer your question, it is not the case that every center is the same. You can have Professor Lee's center. He takes weeks to prepare, and he goes and talks to the committee, stating the importance of the case. And suddenly we are approved to start. In other centers, it could take months. In some centers, it could take half a year. It also involves the administrative burden. This process involves legal reviews. And. It depends on the influence the surgeon has within their hospital and how they can leverage that. It is a fast-track process and so on. So, therefore, it is more or less impossible to answer your question. The worst case I have heard about is nine months to finalize a legal agreement with the hospital. So the only thing I can say is that it takes between one week and nine months for a hospital to get up and running as a site that can pay for the device.
Perfect.
But how? I would guess that now that we have the central IRB approval, the process is more like two to three months for a normal center. Otherwise, we would have already started 25 centers. If it were just a matter of going there and starting the surgeries, that is why we need to complete this process first. But of course, it is not an enormous amount of time. Many of these surgeons are really trying to push this. I think I will have quite a bit more centers here in December coming up. Who organized this? I am expecting maybe another three centers could be ready in December. That is the approximation. And then of course, this will accelerate because we are doing this in parallel. But in the beginning, it is very important that these key surgeons are doing it first. This is politics. You need to give them some headroom, and they are the first to really get going. They could do some publicity around this. They are some of the key surgeons, and we need to start with them. You cannot just roll out every one of the 100 centers at the same time. And you know, it's not politically the way you do it. You need to start with the key top-of-the-line surgeons. And then maybe you start with the next 25 key ones. They feel they are being treated as a little bit special. And then you get going with the 100. So, as I said, I can nearly guarantee you that it will be much more than 100 centers. We want to start when we have reached 100 centers because it is the right time. And we have. Now, I think the surgeon who does the most robotic surgery in the whole United States has written to us and wants to start, for example. And, you know, it is really we have a very we call it headwind or, nay, the opposite, we have a tailwind. Yeah. So, but I think people must respect that. It is a process that needs to be done with quality. It is not just about rushing to start centers. We need to do this very, very carefully to build the foundation for something, you know.
Very clear. No, thanks. And just finally, I appreciate it is really early right now, but within the waiting list that you may have visibility on, are the patients maybe those who have always been planning to do a surgery, regardless of if it was for reflux or the LINX device, or those who were previously reluctant due to the devices on the market. And now, this new approval has been added to the waiting list. I was just trying to understand the early demand and where that is originating from.
I mean, of course, if the doctor, even if a patient has been planned for another procedure, has a meeting with the patient and they see the difference in outcome, you know, it is not a small incremental step of improvement here. From the patient perspective, this is like night and day; with previous procedures, they replaced the reflux with other complications and other side effects. Now they have a procedure that just takes away their disease without adding all these problems. It is very easy to convince the patients. Patients are not our problem. And doctors are not our problem. It is just the formalities that we are working on now. That is why I went step by step. But this, of course, will accelerate because more and more centers can be done in parallel. It is just that we also need to give them some time. The key centers needed a little bit of headroom to start and make some publicity around that. We need to be strategic as well, as we are doing this in the best way for the company and the best way for the investors. I do not think the investors will be unhappy with us going forward here. It is just that you need a little bit of patience and understand that these are things that need to be done.
Very, very clear. And thanks a lot for taking my questions.
Thank you.
There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.
Thank you. We have just received a few questions. Peter, could you please provide an update regarding the RCT?
Yes.
I can do that. So the RCT in this case means that we are doing a comparative study between Nissen fundoplication, which is seen as the standard of care in the guidelines, and RefluxStop. It is just the formalities that we are working on now. That is why I went step by step. But this, of course, will accelerate because we can work with more and more centers in parallel. It is just that we also need to give some. The key centers needed a little bit of headroom to start and make some publicity around that. And we need to be strategic, as we are doing this in the best way for the company and the best way for the investors. And I do not think the investors will be unhappy with us going forward here. It is just that you need a little bit of patience and understand that these are things that need to be done. Very clear. And thanks a lot for taking my questions. Thank you. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments. Thank you. We just have a few questions that came in. Peter, could you please provide an update regarding the RCT? Yes, I can do that. So, the RCT in this case means that we are doing a comparative study between Nissen fundoplication, which is seen as the standard of care in the guidelines, and RefluxStop. So, it is basically a lottery as to which patients get which procedure, and then you compare the outcome. And for this study, we took a break because we wanted to include U.S. centers. So now, we are restarting this RCT. And we will then have U.S. centers coming in. They will come a little bit later because they need, of course, to reach a certain training level. But that is part of the study now, to include these centers. So yes, it is starting now. We are just filing for the update to the Ethics Committee. And then we will start like crazy to do this study. Yes. We initiated a pause in this study because we wanted to include U.S. centers. So now we are restarting this RCT. And we then will have U.S. Centers are coming in. They will come a little bit later because they need to, of course, reach a certain training level. But that is now part of the study to include these centers. So yes, it is starting now. We are just filing for the update to the Ethics Committee. And then we will start to conduct this study. Yes.
Here's another question. I have visited many social platforms with thousands of potential patients. But in this person's opinion, there do not seem to be that many patients who know about RefluxStop. What are our plans to reach out, and when will we see a splash in the market?
So, that is absolutely correct. Of course, the average American does not know about RefluxStop; it is mainly the surgeons who are familiar with it through various medical congresses. But that's where the direct-to-consumer marketing comes in. However, it is ineffective to start with this marketing until you have trained centers. So our goal is to train the first 25 centers. So they are spread all over the United States. And then we can do the DTC marketing on a bit larger scale. We will, of course, start with social media and other activities. And so on. So we will do our best. But the big campaign to let everybody in the United States know about RefluxStop is something we cannot do until we have a widespread number of centers.
How many operations could a U.S. surgeon perform every week?
Yeah. So everything in the United States is larger. They have a larger number of patients that they serve at their hospitals, and they perform more surgeries, much more surgeries than they do in Europe generally. So, as I said, Professor Lipham is said to do 1,100 surgeries, but that's based on more than one surgeon. So he has four more surgeons on his team. And then, of course, they perform varying amounts of surgeries. But generally, you can imagine if you take a one-hour operation, then if you are at a private, very effective hospital, they change the patient in 20 minutes, and then, you know, every 1.5 hours. You have done a procedure, but if you work in a university hospital, maybe they take an hour to change. And then it takes every procedure two hours, and it can even take longer in some extreme examples. And then of course, the doctors have different groups of patients. Sometimes they need to treat cancer patients and so on. But generally, these big centers have more surgeons, so that is why they can achieve these high numbers. I don't know if I answered your question, but generally it is around 500 to 1,000 procedures or so in a hospital. That is the realistic outlook for the hospitals. We are starting up now.
Okay. Final question. Due to time constraints. Would you say that RefluxStop could replace Nissen in the U.S. market and will Nissen disappear? Nissen fundoplication.
I mean, our vision is that we will be the new standard of care and that nearly all operations will be done with RefluxStop. That is sort of our vision. I can give you one example. It is Professor George Zehetner from Inselspital in Bern. He started with RefluxStop, and he only performed it on the very worst cases because he saw those, as I talked to you before, with motility problems and large hiatal hernias, could be good candidates. So he started with those. And over time he has completely switched. So he now performs only RefluxStop basically. I mean, sometimes there could be a patient who is not suitable for RefluxStop, so you perform another procedure, but basically, it is a process. Who was treating them then? You know, maybe over six years, he has come to the conclusion that it's only RefluxStop that counts. And because we have so much better results for all patients, basically. So this is what I foresee will happen in the United States as well. And not only that, but many more patients will be operated on because we have a much larger market. You know, we can operate on all these people who could not be operated on before. And we have a procedure that doesn't have a 50% complication rate. And that is why it is highly likely we can achieve a tenfold increase in this market space. So, I hope I have answered your question. Okay. I am sorry. It has taken us a long time, but we have a few more questions that we didn't have time to answer. But I apologize. I think we cannot go on any longer now. We are already five minutes over one hour. But I really appreciate all of you who support us, and we will do our best to make you happy. But please realize we need to do this professionally. We cannot compromise on quality, but time is on our side. Thank you very much for listening. Goodbye.



















